Efficacy and Safety of Mate Extracts on Decrement of Body and Abdominal Fat in Obese Subjects

Mate Extract Supplementation Reduces Body and Abdominal Fat in Obese Korean Subjects

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01778257

Enrollment

Registered

2013-01-29

Start date

2011-10-31

Completion date

2012-03-31

Last updated

2013-01-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity

Keywords

Mate extracts, Obesity, abdominal fat

Brief summary

Obesity is a major health issue worldwide; there is a constant raise in obesity related death each year.

Detailed description

The primary aim of the study was to investigate the effect of Mate extracts in Korean subjects on body fat and abdominal fat, double blind, placebo-controlled clinical trial. Thirty obesity subjects with BMI ≥ 25 kg/㎡ and waist-hip ratio (WHR)≥ 0.90 for men and ≥ 0.85 for women were for 12 weeks.

Interventions

DIETARY_SUPPLEMENTMate extract

Mate is a South American herb that is traditionally prepared as a tea and used, among others, for weight reduction.

DIETARY_SUPPLEMENTPlacebo

Amount and calorie of placebo are same with Mate extracts.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

19 Years to 65 Years

Healthy volunteers

Yes

Inclusion criteria

* Volunteers aged 19 to 65 years * 25 kg/m2 ≤ BMI ≥35 kg/m2 * Ability to give informed consent

Exclusion criteria

* Significant variation in weight (more 10%) in the past 3 month * Cardiovascular disease, neurologic or psychiatric disease, renal, pulmonary and hepatic abnormalities * History of disease that could interfere with the test products or impede their absorption, such as gastrointestinal disease (Crohn's disease) or gastrointestinal surgery (a caesum or enterocele surgery are included) * Laboratory test, medical or psychological conditions deemed by the investigators to interfere with successful participation in the sutdy * Allergic or hypersensitive to any of the ingredients in the test products * Pregnancy or breast feeding * Used antipsychosis drugs therapy within past 2 months * History of alcohol or substance abuse (21 units/week over) * Participation in any other clinical trials within past 3 months

Design outcomes

Primary

Measure	Time frame
Changes in body and abdominal fat	body fat: baseline, 6 weeks and 12 weeks, abdominal fat of CT: baseline and 12 weeks

Secondary

Measure	Time frame
Changes in anthropometric parameters(weight, BMI, waist and hip circumference)	baseline, 6 weeks and 12 weeks
Changes in blood lipid profile(total cholesterol, triglyceride, HDL-cholesterol, LDL-cholesterol, free fatty acid)	baseline, 6 weeks and 12 weeks

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 15, 2026